LexaGene Holdings Inc. buy Subdi
Start price
11.02.21
/
50%
€0.92
Target price
11.02.22
€2.00
Performance (%)
-52.92%
End price
20.04.21
€0.44
Summary
This prediction ended on 20.04.21 with a price of €0.44. The BUY prediction by Subdi for LexaGene Holdings Inc. performed very badly with a performance of -52.92%. Subdi has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| LexaGene Holdings Inc. | - | - | - | - |
| iShares Core DAX® | -0.205% | 2.528% | 16.157% | 18.725% |
| iShares Nasdaq 100 | 1.613% | 4.733% | 30.626% | 56.133% |
| iShares Nikkei 225® | -0.740% | 0.396% | 9.039% | 5.948% |
| iShares S&P 500 | 0.267% | 2.720% | 26.333% | 47.720% |
Comments by Subdi for this prediction
In the thread LexaGene Holdings Inc. diskutieren
Is LexaGene The Perfect Stock?
Feb. 5, 2021 11:54 AM ET | 111 comments | About: Lexagene Hldgs Inc. (LXXGF), Includes: BGNE, EFLVF, GNMK
Summary
- LexaGene has just started sales of a revolutionary automated PCR machine that can test for 27 pathogens at once in about one hour.
- It parallels Electrovaya, which have a recent 15 bagger on, a value nanocap stock in a highly favored sector that is likely to go profitable and have extreme growth.
- I can find nothing wrong with the company as the management, market, technology and execution are all excellent.Timing is perfect, they have just started sales with a $billion+ sales potential product and FDA approval to enter the POC market is possible in May. ...
Artikel von Darp Research ohne Paywall:
- 16 Oct, 2016 | 20:59
Wolfeye Resource completes reverse takeover, exits mining
LexaGene Holdings Inc., formerly Wolfeye Resource Corp., said Oct. 14 that it completed its previously announced reverse takeover transaction in which it acquired Bionomics Diagnostics Inc.
Following the deal, the company issued 20 million common shares at a deemed price of 25 Canadian cents per share in exchange for all issued and outstanding securities of Bionomics Diagnostics.
Additionally, the company changed its name to LexaGene Holdings, effective Oct. 12. LexaGene shares will begin trading on the TSX Venture Exchange as a tier 2 technology issuer under the symbol LXG.
Wolfeye will exit mining operations and will be known as a startup biotechnology company due to the move.
https://www.spglobal.com/marketintelligence/en/news-insights/blog/industry-top-trends-2021-metals-and-mining
https://www.spglobal.com/marketintelligence/en/news-insights/blog/industry-top-trends-2021-metals-and-mining